| Literature DB >> 22072903 |
Hai Zhong Huo1, Bing Wang, Yong Kang Liang, Yong Yang Bao, Yan Gu.
Abstract
Licorice has been used in Chinese folk medicine for the treatment of various disorders. Licorice has the biological capabilities of detoxication, antioxidation, and antiinfection. In this study, we evaluated the antihepatotoxic effect of licorice aqueous extract (LE) on the carbon tetrachloride (CCl(4))-induced liver injury in a rat model. Hepatic damage, as reveled by histology and the increased activities of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) activities, and decreased levels of serum total protein (TP), albumin (Alb) and globulin (G) were induced in rats by an administration of CCl(4) at 3 mL/kg b.w. (1:1 in groundnut oil). Licorice extract significantly inhibited the elevated AST, ALP and ALT activities and the decreased TP, Alb and G levels caused by CCl(4) intoxication. It also enhanced liver super oxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), Glutathione S-transferase (GST) activities and glutathione (GSH) level, reduced malondialdehyde (MDA) level. Licorice extract still markedly reverses the increased liver hydroxyproline and serum TNF-α levels induced by CCl(4) intoxication. The data of this study support a chemopreventive potential of licorice extract against liver oxidative injury.Entities:
Keywords: AST; CCl4; antioxidant; licorice; liver; rat
Mesh:
Substances:
Year: 2011 PMID: 22072903 PMCID: PMC3210994 DOI: 10.3390/ijms12106529
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Effect of licorice aqueous extract (LE) treatment on experimental rats’ average body weight gain and food utilization rate (n = 10).
| Group | Initial body weight (g) | Final body weight (g) | Average body weight gain (g) | Food utilization rate (%) |
|---|---|---|---|---|
| 0 (mg/kg b.w./day) | 236.6 ± 29.9 | 287.5 ± 30.1 | 49.83 ± 5.07 | 34.75 ± 3.72 |
| 50 (mg/kg b.w./day) | 241.7 ± 35.3 | 281.9 ± 28.9 | 49.35 ± 5.32 | 33.98 ± 2.17 |
| 100 (mg/kg b.w./day) | 238.8 ± 27.4 | 289.6 ± 30.6 | 50.02 ± 4.78 | 35.03 ± 3.08 |
| 150 (mg/kg b.w./day) | 239.5 ± 26.2 | 289.2 ± 32.8 | 49.17 ± 5.19 | 33.47 ± 2.96 |
| 200 (mg/kg b.w./day) | 240.5 ± 31.1 | 288.1 ± 30.7 | 50.07 ± 4.53 | 34.14 ± 3.14 |
| 250 (mg/kg b.w./day) | 237.2 ± 28.3 | 289.1 ± 32.1 | 50.22 ± 4.62 | 35.38 ± 2.26 |
| 300 (mg/kg b.w./day) | 235.7 ± 26.7 | 287.4 ± 29.4 | 49.43 ± 4.73 | 35.73 ± 2.51 |
Figure 1Histological Analysis of the Livers after CCl4 Administration. Typical images were chosen from the different experimental groups (original magnification 400×). (A) Control group; (B) vehicle-treated CCl4 group; (C) CCl4 and LE (150 mg/kg)-treated group; (D) CCl4 and LE (300 mg/kg)-treated group And (E) CCl4 and bifendate (100 mg/kg)-treated group.
Effect of LE on serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total protein (TP), albumin (Alb) and globulin (G) levels in different groups.
| Group | AST (U/L) | ALT (U/L) | ALP (U/L) | TP (mg/L) | Alb (mg/L) | G (mg/L) |
|---|---|---|---|---|---|---|
| NC | 171.82 ± 13.54 | 22.13 ± 1.75 | 123.85 ± 11.08 | 71.54 ± 4.07 | 39.61 ± 2.08 | 31.22 ± 2.02 |
| MC (CCl4) | 401.45 ± 32.07 | 241.62 ± 2.03 | 401.52 ± 32.98 | 51.26 ± 3.62 | 30.11 ± 1.65 | 19.84 ± 1.54 |
| CCl4 + LE (100 mg/kg b.w.) | 289.32 ± 20.19 | 92.57 ± 7.33 | 299.64 ± 29.83 | 60.05 ± 6.83 | 33.07 ± 2.39 | 23.18 ± 1.42 |
| CCl4 + LE (150 mg/kg b.w.) | 297.14 ± 22.14 | 98.41 ± 6.05 | 316.73 ± 27.05 | 64.03 ± 4.42 | 34.15 ± 2.64 | 25.13 ± 1.66 |
| CCl4 + LE (300 mg/kg b.w.) | 193.17 ± 14.71 | 41.09 ± 2.64 | 198.37 ± 12.56 | 69.32 ± 4.91 | 38.53 ± 3.15 | 29.94 ± 2.06 |
| CCl4 + bifendate | 253.05 ± 19.06 | 52.61 ± 3.35 | 194.02 ± 10.47 | 66.38 ± 7.03 | 36.64 ± 1.96 | 30.17 ± 2.36 |
P < 0.01, compared with NC group;
P < 0.01;
P < 0.01, compared with CCl4-treated group. NC: normal control, MC: model control.
Effect of LE on liver index in different groups.
| Group | Liver index |
|---|---|
| NC | 3.41 ± 0.28 |
| MC (CCl4) | 4.95 ± 0.22 |
| CCl4 + LE (100 mg/kg b.w.) | 4.34 ± 0.38 |
| CCl4 + LE (150 mg/kg b.w.) | 4.03 ± 0.42 |
| CCl4 + LE (300 mg/kg b.w.) | 3.56 ± 0.31 |
| CCl4 + bifendate | 3.48 ± 0.29 |
P < 0.01, compared with NC group;
P < 0.05;
P < 0.01, compared with CCl4-treated group; NC: normal control.
Effect of LE on liver hydroxyproline levels in different groups.
| Group | Hyp (μg·g−1) |
|---|---|
| NC | 99.32 ± 7.05 |
| MC (CCl4) | 413.17 ± 33.76 |
| CCl4 + LE (100 mg/kg b.w.) | 342.32 ± 20.17 |
| CCl4 + LE (150 mg/kg b.w.) | 306.15 ± 26.08 |
| CCl4 + LE (300 mg/kg b.w.) | 174.63 ± 13.64 |
| CCl4 + bifendate | 149.27 ± 11.07 |
P < 0.01, compared with NC group;
P < 0.01, compared with CCl4-treated group; NC: normal control.
Effect of LE on liver malondialdehyde (MDA) and glutathione (GSH) levels in different groups.
| Group | MDA (nmol/mg Prot) | GSH (mg/g Prot) |
|---|---|---|
| NC | 4.32 ± 2.13 | 154.29 ± 13.29 |
| MC (CCl4) | 8.54 ± 4.83 | 88.16 ± 6.72 |
| CCl4 + LE (100 mg/kg b.w.) | 7.39 ± 4.51 | 104.32 ± 10.63 |
| CCl4 + LE (150 mg/kg b.w.) | 6.01 ± 4.21 | 127.39 ± 11.05 |
| CCl4 + LE (300 mg/kg b.w.) | 4.17 ± 3.09 | 150.73 ± 13.29 |
| CCl4 + bifendate | 5.73 ± 3.71 | 144.37 ± 11.73 |
P < 0.01, compared with NC group;
P < 0.05,
P < 0.01, compared with CCl4-treated group; NC: normal control.
Effect of LE on liver antioxidant enzymes activities in different groups.
| Group | SOD (U/mg prot) | CAT (U/mg prot) | GSH-Px (U/mg prot) | GR (U/g prot) | GST (nmol/min/mg prot) |
|---|---|---|---|---|---|
| NC | 164.9 ± 12.67 | 32.65 ± 3.05 | 27.51 ± 1.85 | 31.43 ± 1.65 | 43.54 ± 4.21 |
| MC (CCl4) | 83.2 ± 5.09 | 16.93 ± 1.52 | 10.73 ± 1.05 | 13.16 ± 1.25 | 21.34 ± 1.85 |
| CCl4 + LE (100 mg/kg b.w.) | 103.9 ± 8.01 | 20.11 ± 1.67 | 15.75 ± 1.93 | 21.85 ± 1.21 | 31.54 ± 2.86 |
| CCl4 + LE (150 mg/kg b.w.) | 114.5 ± 8.23 | 22.07 ± 1.88 | 19.32 ± 1.43 | 22.43 ± 1.07 | 34.21 ± 2.53 |
| CCl4 + LE (300 mg/kg b.w.) | 159.2 ± 11.72 | 30.57 ± 2.53 | 26.19 ± 1.97 | 30.41 ± 2.63 | 41.83 ± 3.92 |
| CCl4 + bifendate | 142.1 ± 10.61 | 27.58 ± 2.22 | 24.62 ± 2.31 | 29.42 ± 1.84 | 36.1 ± 4.17 |
P < 0.01, compared with NC group;
P < 0.05;
P < 0.01, compared with CCl4-treated group; NC: normal control.
Effect of LE on serum TNF-α levels in different groups.
| Group | TNF-α (pg/mL) |
|---|---|
| NC | 202.15 ± 17.84 |
| MC (CCl4) | 993.14 ± 85.13 |
| CCl4 + LE (100 mg/kg b.w.) | 831.66 ± 75.42 |
| CCl4 + LE (150 mg/kg b.w.) | 703.12 ± 65.09 |
| CCl4 + LE (300 mg/kg b.w.) | 483.19 ± 37.24 |
| CCl4 + bifendate | 503.91 ± 46.18 |
P < 0.01, compared with NC group;
P < 0.01, compared with CCl4-treated group; NC: normal control.